Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

Am J Med. 1986 May;80(5):884-90. doi: 10.1016/0002-9343(86)90633-9.

Abstract

Selective antimicrobial decontamination with norfloxacin was compared with vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients. In the group of patients receiving norfloxacin, there were a lower number of acquired gram-negative bacillary organisms per patient (0.88 versus 1.86, p = 0.002), fewer patients with documented infection (16 of 36 versus 20 of 30, p = 0.12), and fewer cases of gram-negative septicemia (0 of 36 versus five of 30, p = 0.02). Norfloxacin was better tolerated (30 of 36 versus 16 of 30 patients highly compliant, p = 0.02), and associated with fewer gastrointestinal side effects (eight of 36 versus 14 of 36 patients, p = 0.07). These results suggest that norfloxacin is a more tolerable and efficacious oral antimicrobial agent than vancomycin/polymyxin for the prevention of serious gram-negative bacillary infections in granulocytopenic patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Agranulocytosis / complications*
  • Agranulocytosis / microbiology
  • Bacterial Infections / prevention & control*
  • Drug Evaluation
  • Drug Tolerance
  • Female
  • Gram-Negative Bacteria
  • Gram-Positive Bacteria
  • Humans
  • Male
  • Middle Aged
  • Mycoses / prevention & control
  • Norfloxacin / adverse effects
  • Norfloxacin / therapeutic use*
  • Nystatin / therapeutic use
  • Polymyxins / therapeutic use*
  • Vancomycin / therapeutic use*

Substances

  • Polymyxins
  • Nystatin
  • Vancomycin
  • Norfloxacin